Novellia Unveils AI-Driven Collaborative Research Effort to Redefine Breast Cancer Treatment

Novellia, Inc., a leading provider of AI-powered health data solutions, has unveiled Project EVEREST, a groundbreaking initiative designed to improve adherence to clinical guidelines in breast cancer care. This cross-industry collaboration aims to address persistent gaps in the treatment of early and metastatic breast cancer by uniting researchers, clinicians, and top biopharmaceutical companies.

Partners in the initiative include industry leaders such as Daiichi Sankyo, Genentech, and AstraZeneca, who will work alongside Novellia to identify and overcome the barriers that prevent consistent, evidence-based care across diverse healthcare environments.

At the heart of Project EVEREST is the development of the first AI-enabled, patient-permissioned longitudinal registry focused specifically on real-world treatment adherence in breast cancer. By assembling a broad coalition across sectors, the initiative seeks to establish a new gold standard for quality improvement research in oncology.

Leveraging Novellia’s proprietary AI platform, Project EVEREST will integrate complex medical histories from NCI-designated cancer centers, laboratories, and regional health systems into a unified, longitudinal patient registry. This robust dataset will support in-depth analysis by researchers at the University of Alabama at Birmingham (UAB), who will work to uncover care delivery trends, identify gaps in the use of current treatment guidelines, and generate targeted recommendations for improving consistency and outcomes in breast cancer treatment.

"The key question we aim to answer is what systemic and clinical factors are preventing patients from receiving the most current, evidence-based care for breast cancer," said Dr. Humaira Sarfraz, Assistant Professor of Medicine and clinician-educator in the Division of Hematology and Oncology at the UAB Medical Center. "The field of oncology is moving at an unprecedented rate, and next-generation, AI-enabled data platforms open up possibilities for us to drive better outcomes for patients by examining real-world data along with patient medical histories and pinpoint where care may fall short in ways that were previously impossible or time-prohibitive."

"When biopharma teams face questions others can't answer, they turn to Novellia for our unique ability to build full, sequential patient stories that reveal hidden insights traditional data providers aren't equipped to find. Project EVEREST builds on our reputation as the only data partner that goes deep enough to solve the toughest challenges in healthcare," said Shashi Shankar, CEO and co-founder of Novellia. "In the past, building these sorts of longitudinal datasets would have cost tens of millions of dollars and required several months of manual data processing by teams of clinical abstractors. By using AI to autonomously unify fragmented health histories and surface critical blind spots missed by traditional real-world data solutions, we're closing the gap between data and decisions. Project EVEREST brings together biopharma leaders, top researchers, and our AI-enabled platform to deliver a scalable model for evidence-based care improvement in breast cancer—and a roadmap for addressing care variation across other complex diseases."

The program will enroll early and metastatic breast cancer patients, including those with HER2+ and HR+/HER2- subtypes. Over a 24-month period, researchers will aggregate and analyze hundreds of thousands of retrospective and prospective patient records to identify trends and deviations from established treatment guidelines. In Phase 2, researchers will then deliver tailored, evidence-based interventions to support health systems and community oncologists in optimizing care delivery, advancing the standard of care through measurable, real-world impact and improved patient outcomes.